Teva Pharmaceutical Industries Ltd articles over last 30 days

- articles last 30 days - articles per day
Mentioned in this news Places Companies People
2015/01/27 15:52
2015/01/27 15:52
19h
Trying to keep some investors happy, Pfizer noted that it returned nearly $12 billion to shareholders through share buybacks and dividends in 2014. For most of a year, Pfizer has been searching for a...
2015/01/27 15:52
2015/01/27 15:52
Latest videos
2015/01/27 14:09
2015/01/27 14:09
20h
Pfizer Inc., the biggest U.S. drug maker, forecast a decline in sales this year as patent expirations and a stronger dollar weigh on revenue. Sales will reach $44.5 billion to $46.5 billion, this...
2015/01/21 21:39
2015/01/21 21:39
6d
WASHINGTON — The Supreme Court has sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug. The...
2015/01/21 06:27
2015/01/21 06:27
7d
... is a daily report on global news about patents, trademarks, copyright and other intellectual-property topics. To be sent this column daily, click SALT IPREPORT .) (Bloomberg) -- Teva...
2015/01/20 16:30
2015/01/20 16:30
7d
... -- Teva Pharmaceutical Industries Ltd. won a U.S. Supreme Court patent ruling that will help it forestall generic competition to its top-selling Copaxone multiple- sclerosis drug. Voting...
2015/01/07 23:08
2015/01/07 23:08
20d
... -- Novartis AG’s imitation of Amgen Inc.’s cancer drug Neupogen won the backing of U.S. advisers, taking a step closer to becoming the first biosimilar drug for sale in the...
2015/01/06 23:17
2015/01/06 23:17
21d
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the Food and Drug Administration (FDA) approval and the launch of the generic equivalent to Diovan® (Valsartan)...
2015/01/05 14:27
2015/01/05 14:27
22d
... -- The first attempt in the U.S. to bring to market cheaper imitations of expensive biologic drugs gained support from U.S. regulators. Novartis AG’s imitation, or biosimilar, is “highly...
Read more at Swissinfo, Market Watch
2014/12/31 08:08
2014/12/31 08:08
28d
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it has executed an initial agreement with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) to regain rights to custirsen, an...
2015/01/27 15:52
2015/01/27 15:52
Latest from Twitter